<DOC>
	<DOCNO>NCT02892604</DOCNO>
	<brief_summary>A new version DiAs artificial pancreas ( AP ) system developed view wide scale outpatient trial . Denominated inControl , include improve user interface communication module closed-loop algorithm remain similar . During pilot study , investigator evaluate new version AP two-week period patient use closed-loop insulin delivery 24/7 The main goal train clinical team new system collect patient opinion system acceptance questionnaire . If trial conclusive , randomize 6-month multicentre study include 240 patient initiate . A total 5 patient include train study 4-week period .</brief_summary>
	<brief_title>Study Feasibility Permanent Use inControl Treatment Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 1 diabetes mellitus since one year , treat insulin since least one year Treatment insulin pump since least 6 month Glycated hemoglobin ( HbA1c ) 10.5 % inclusion visit For woman child bearing age , current pregnancy use efficient contraception whole research participation Agreement use drug product use reduction blood glucose level , metformin GLP1 analog , except therapy use least 3 month study start Agreement stop closedloop insulin delivery acetaminophen use 4 following hour Agreement suspend use patient CGM device study period study CGM use Access internet mobile phone network home Agreement follow study procedure Affiliation French social security system similar healthcare coverage system Mandatory write informed consent Need chronic use acetaminophen Start use drug product use reduction blood glucose level , metformin GLP1 analogs 3 month inclusion Hemophilia coagulation disorder Psychological and/or cognitive trouble may impair appropriate follow study procedure Diabetic ketoacidosis last 6 month Acute cardiovascular event last 12 month Severe hypoglycaemia convulsion loss conscience last 12 month Use therapy significant impact glucose metabolism Cystic fibrosis Lack nearby thirdparty assistance availability case trouble Malignant disease , except consider cured since least 10 year Impaired kidney function ( serum creatinin &gt; 150 umol/L ) Impaired liver status ( ALAT ASAT &gt; 2times upper normal limit ) Active gastroparesis Acute adrenocortical event Alcohol narcotic abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>artificial pancreas</keyword>
	<keyword>closed-loop insulin infusion</keyword>
</DOC>